Ended Therapeutic confirmatory (Phase III) Triple Negative Breast Cancer

Phase 3 Study of Adagloxad Simolenin (OBI-822)/OBI-821 Treatment for Breast Cancer Patients

EU CTIS ID: 2023-508755-39-00

What this study is testing

To determine the effect of adagloxad simolenin (OBI-822)/OBI-821 treatment on improving invasive disease-free survival (IDFS) in the study population.

Therapeutic confirmatory (Phase III)

A plain-language read of the study's public EU CTIS listing. The study team confirms the details.

Who can take part

You may be able to join if

1. Male or female patient ≥18 years.
10. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
11. Females must be either of non-childbearing potential, i.e., surgically sterilized (have documented sterilization, bilateral oophorectomy /salpingectomy at least 3 months before the start of the trial and/or hysterectomy), or one year postmenopausal; or if of childbearing potential must have a negative pregnancy test (urine or serum) at screening.
12. Males and females of childbearing potential and their partners must be willing to use effective contraception during the entire study Treatment Phase and for at least 4 weeks (28 days) after the last dose of study treatment.
13. Adequate hematological, hepatic and renal function as defined below: - Absolute neutrophil count (ANC) ≥1,500/μL - Platelets ≥75,000/μL - Hemoglobin ≥8.5 g/dL - Serum creatinine ≤1.5 × upper limit of normal (ULN) or calculated Creatinine clearance ≥55 mL/min for patients with creatinine levels >1.5 ×institutional ULN (glomerular filtration rate can also be used in place of creatinine or creatinine clearance may be calculated per institutional standard) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN - Alkaline phosphatase (ALP) ≤2.5 × ULN - Serum total bilirubin ≤1.5 × ULN (unless Gilbert's disease is documented).
14. Consent to participate with a signed and dated Institutional Review Board /Independent Ethics Committee -approved patient informed consent for the study prior to beginning any specific study procedures.

You likely can't join if

1. Local recurrence of or previous history of any ipsilateral or contralateral invasive breast cancer within 10 years prior to randomization [for synchronous tumors see Exclusion Criteria #3].
10. Any known hypersensitivity to active/inactive ingredients in the study drug formulation or known severe allergy or anaphylaxis to fusion proteins.
11. Prior receipt of a glycoconjugate vaccine for cancer immunotherapy.
12. Known history or positive for human immunodeficiency virus (HIV) positive, unless on effective anti-retroviral therapy with undetectable viral load within 6 months of therapy (note: HIV testing is not required for study entry).
13. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to randomization. Patients who have completed curative therapy and have undetectable viral load for HCV are eligible. For patients with evidence of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy. (note: HBV/HCV testing is not required for study entry).
14. Any condition, including significant diseases and/or laboratory abnormalities that would place the patient at unacceptable risk for study participation.

See the full eligibility criteria

Who can join

1. Male or female patient ≥18 years.
10. Eastern Cooperative Oncology Group (ECOG) performance status ≤1.
11. Females must be either of non-childbearing potential, i.e., surgically sterilized (have documented sterilization, bilateral oophorectomy /salpingectomy at least 3 months before the start of the trial and/or hysterectomy), or one year postmenopausal; or if of childbearing potential must have a negative pregnancy test (urine or serum) at screening.
12. Males and females of childbearing potential and their partners must be willing to use effective contraception during the entire study Treatment Phase and for at least 4 weeks (28 days) after the last dose of study treatment.
13. Adequate hematological, hepatic and renal function as defined below: - Absolute neutrophil count (ANC) ≥1,500/μL - Platelets ≥75,000/μL - Hemoglobin ≥8.5 g/dL - Serum creatinine ≤1.5 × upper limit of normal (ULN) or calculated Creatinine clearance ≥55 mL/min for patients with creatinine levels >1.5 ×institutional ULN (glomerular filtration rate can also be used in place of creatinine or creatinine clearance may be calculated per institutional standard) - Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤3 × ULN - Alkaline phosphatase (ALP) ≤2.5 × ULN - Serum total bilirubin ≤1.5 × ULN (unless Gilbert's disease is documented).
14. Consent to participate with a signed and dated Institutional Review Board /Independent Ethics Committee -approved patient informed consent for the study prior to beginning any specific study procedures.
15. Ability to understand and willingness to complete all protocol required procedures.
2. Documented radiographic and histopathologic confirmed primary localized invasive breast cancer.
3. Histologically documented TNBC (estrogen receptor-negative [ER-] / progesterone receptor-negative [PR-] / human epidermal growth factor 2-negatove [HER2-]) defined as ER-negative and PR-negative (≤5% positive cells stain by IHC for both ER and PR), and negative HER2/neustatus, confirmed on tumor sample. HER2/neu-negative will be defined as one of the following criteria: - IHC 0 or 1+ - Single-probe average HER2 gene copy number of <6 signals/nucleus - (ISH concordance with FISH HER2/neu chromosome 17 (CEP17) non-amplified ratio of <2.
4. Globo H IHC H-score ≥15 from the residual primary site/or lymphnode (if primary site is not available) tumor obtained at the time ofdefinitive surgery or initial diagnosis (only if surgical tumor sample is not available). Globo H expression will be determined during prescreening by a central laboratory. Instructions for submission of slides/tumor tissue blocks are provided in the protocol and study Lab Manual.
5. No evidence of metastatic disease in chest, abdomen, and pelvis by CT or other adequate imaging during the Screening Phase. Imaging within 3 months prior to randomization is acceptable as baseline scan. Bone scans and imaging of the brain at screening is optional, and should be symptom directed.
6. High-risk patients with no evidence of disease after completing standard treatment and meeting ONE of the following criteria: - Neoadjuvant chemotherapy followed by definitive surgery: Residual invasive disease following neoadjuvant chemotherapy defined as: A contiguous focus of residual invasive cancer in the surgical breast specimen measuring ≥1 cm in diameter and/or with residual invasive cancer in at least one axillary node (micrometastases or macrometastases), as determined by local pathology review. - Definitive surgery followed by adjuvant chemotherapy: Pathological Prognostic Stage IIB, Stage IIIA, IIIB, or Stage IIIC disease according to the 8th edition of the American Joint Committee on Cancer (AJCC) Cancer Staging Manual.
7. Must have completed at least 4 cycles of a standard taxane and anthracycline-based multi-agent chemotherapy regimen (or a taxaneonly regimen if the patient is ineligible for anthracycline treatment) either in the neoadjuvant or adjuvant setting (e.g., National Comprehensive Cancer Network recommended regimens).
8. Randomization must occur (a) within 16 weeks after definitive surgery and radiation therapy (if radiation therapy administered) in patients who received neoadjuvant multiagent chemotherapy or, (b) for patients receiving adjuvant multiagent chemotherapy (not including capecitabine, immune checkpoint inhibitor), within 16 weeks after the completion of the adjuvant multiagent chemotherapy and radiation therapy (if radiation therapy administered). Note: patients may be randomized and initiate study treatment concurrent with adjuvant SOC therapy (observation, capecitabine; immune checkpoint inhibitor ± capecitabine).
9. All treatment-related toxicities resolved to Grade <1 on National Cancer Institute-Common Terminology Criteria for Adverse Events (version 5.0) criteria (except hair loss and ≤Grade 2 neuropathy, which are acceptable).

What rules you out

1. Local recurrence of or previous history of any ipsilateral or contralateral invasive breast cancer within 10 years prior to randomization [for synchronous tumors see Exclusion Criteria #3].
10. Any known hypersensitivity to active/inactive ingredients in the study drug formulation or known severe allergy or anaphylaxis to fusion proteins.
11. Prior receipt of a glycoconjugate vaccine for cancer immunotherapy.
12. Known history or positive for human immunodeficiency virus (HIV) positive, unless on effective anti-retroviral therapy with undetectable viral load within 6 months of therapy (note: HIV testing is not required for study entry).
13. Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection prior to randomization. Patients who have completed curative therapy and have undetectable viral load for HCV are eligible. For patients with evidence of chronic HBV infection, the HBV viral load must be undetectable on suppressive therapy. (note: HBV/HCV testing is not required for study entry).
14. Any condition, including significant diseases and/or laboratory abnormalities that would place the patient at unacceptable risk for study participation.
15. Currently pregnant or breastfeeding women.
16. Currently participating in or has participated in a breast cancer therapeutic clinical trial within 4 weeks (28 days) prior to randomization.
2. Definitive clinical or radiologic evidence of metastatic disease.
3. Synchronous bilateral breast cancer, unless both tumors are confirmed as TNBC.
4. Have received any anti-cancer vaccines.
5. Concomitant treatment with anticancer therapy other than adjuvant SOC therapy (capecitabine; immune checkpoint inhibitor), or other investigational therapy, if expected during the study.
6. A history of other malignancies (except appropriately treated melanoma in situ, non-melanoma skin carcinoma, carcinoma in situ of the uterine cervix, follicular or papillary thyroid cancer or other nonbreast malignancies with a similar outcome to those mentioned above) within 5 years prior to randomization.
7. Have any active autoimmune disease or disorder that requires Systemic immunosuppressive/immunomodulatory therapy. NOTE: Autoimmune diseases that are confined to the skin (e.g., psoriasis) that can be treated with topical steroids alone are allowed during the study.
8. Oral/parenteral corticosteroid treatment (>5 mg/day of prednisone /equivalent), within 2 weeks prior to randomization or anytime during the study. NOTE: inhaled steroids for treatment of asthma; and topical steroids are allowed.
9. Any known uncontrolled concurrent illness that would limit compliance with study requirements, including but not limited to ongoing or active infections, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, psychiatric disorders, or substance abuse.

The study team makes the final eligibility decision.

Where it's taking place

Russian Federation
China
Peru
Australia
Mexico
Hong Kong
Ukraine
United States
Brazil
Korea, Republic of
Taiwan
South Africa

Questions & answers

Do participants get paid in this trial?

This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.

Is it free to join, and do I need insurance?

Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.

How long does this study last?

The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.

Who can join this trial?

This study is enrolling all sexes, 18-64 years, 65+ years. The study team makes the final eligibility decision.

Where is this trial taking place?

Study sites include Russian Federation; China; Peru; Australia; Mexico; Hong Kong and 6 more location(s). Enter your location above to see the nearest site and check your eligibility.

Explore other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH)Heart failure Coronary artery disease

BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.